In March 2025, the company introduced new options for the immediate-to-buyer offering of its Wegovy weight loss drug. The company established a whole new pharmacy, named NovoCare, which would charge prospects $499 monthly for access to the drug, less than half the expense of the drug via other pharmaceutical distribution networks.[fifty three]This